Abbott to acquire Sanofi Carpuject injectable system, multi-source line for about $200 mil.

Executive Summary

ABBOTT TO ACQUIRE SANOFI CARPUJECT INJECTABLE LINE FOR APPROXIMATELY $200 MIL. in a deal expected to close this summer, Abbott said April 29. The acquisition will give Abbott worldwide rights to Sanofi's Carpuject line of pre-filled, single-dose syringes. In addition to Carpuject, Abbott will obtain Sanofi's line of multi-source injectable drugs, including anesthetics such as Marcaine (bupivacaine), analgesics, central nervous system drugs and cardiovascular drugs. Sanofi's Primacor (milrinone lactate) and Inocor (amrinone lactate) injections are not included in the deal.